Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023
Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase…
Vanda Pinto, PhD, science writer — 
Articles by Vanda Pinto
1st Patient Dosed in Phase 1/2 Trial of Antibody Therapy ISB 1442
The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with…
Talquetamab Named a Breakthrough Therapy for Hard-to-treat Myeloma
Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA)…
Agreement Reached to Develop MMP-13 Inhibitors to Treat Myeloma
SteroTherapeutics has entered into an exclusive license agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation to develop matrix metalloproteinase 13…